Core Viewpoint - Kangtai Biological (300601) announced the termination of its collaboration with AstraZeneca Investment (China) Co., Ltd. to establish a joint venture in the vaccine sector, stating that this decision will not have a significant adverse impact on the company [1][4]. Group 1: Termination of Joint Venture - The collaboration plan between Kangtai Biological and AstraZeneca began in March 2025, aiming to establish a joint venture in Beijing with a registered capital of approximately 345 million yuan (about 50 million USD) [4]. - The joint venture was intended to focus on vaccine business and both parties were to hold 50% equity, with a total investment of around 400 million USD (approximately 2.76 billion yuan) [4]. - The decision to terminate the collaboration was due to significant changes in the market environment and high investment risks in the vaccine industry, as assessed by both parties [4]. Group 2: Financial Impact and Future Strategy - Kangtai Biological emphasized that since no actual investment had been made, the termination will not significantly affect the company's existing business, financial status, or operational conditions [5]. - The company plans to continue its dual-driven strategy of "internal innovation + external expansion," integrating internal and external resources to enhance its international business layout [5]. - Kangtai Biological's main business includes the research, production, and sales of human vaccines, with key products such as the 13-valent pneumococcal conjugate vaccine and the combined vaccine for whooping cough, diphtheria, and tetanus [5]. Group 3: Recent Financial Performance - On January 29, Kangtai Biological released a performance forecast, expecting a net profit attributable to shareholders for 2025 to be between 49 million and 73 million yuan, representing a decline of 75.70% to 63.80% compared to the previous year [6][7]. - The forecasted net profit after deducting non-recurring gains and losses is expected to be between 51.5 million and 76.5 million yuan, reflecting a decrease of 79.06% to 68.90% year-on-year [6][7]. - The decline in profits is attributed to increased marketing efforts in the domestic market, international strategy implementation, rising operating costs, and increased R&D investments [7].